Prasugrel 5 mg inhibits platelet P-selectin and GPIIb–IIIa expression in very elderly and non elderly : results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients
(2016) In Journal of Thrombosis and Thrombolysis 42(3). p.369-375- Abstract
Platelet P-selectin and activated glycoprotein IIb–IIIa (GPIIb–IIIa) are markers of platelet activation and mediates platelet aggregation. Prasugrel (Pras) 5 mg may be used in very elderly (VE) acute coronary syndrome (ACS) patients undergoing PCI, but its effect on platelet P-selectin and activated GPIIb–IIIa in those patients is not known. Stable ACS patients, VE (78 ± 5 years, n = 23) and non-elderly (NE) (55 ± 5 years, n = 22) were randomized to Pras (5 or 10 mg) or clopidogrel (Clop) 75 mg during three 12-day periods. Platelet activation markers were measured by flow cytometry on unstimulated or stimulated (adenosine diphosphate (ADP) 20 μM) platelets, before and after each dosing period.Results: At baseline there was no difference... (More)
Platelet P-selectin and activated glycoprotein IIb–IIIa (GPIIb–IIIa) are markers of platelet activation and mediates platelet aggregation. Prasugrel (Pras) 5 mg may be used in very elderly (VE) acute coronary syndrome (ACS) patients undergoing PCI, but its effect on platelet P-selectin and activated GPIIb–IIIa in those patients is not known. Stable ACS patients, VE (78 ± 5 years, n = 23) and non-elderly (NE) (55 ± 5 years, n = 22) were randomized to Pras (5 or 10 mg) or clopidogrel (Clop) 75 mg during three 12-day periods. Platelet activation markers were measured by flow cytometry on unstimulated or stimulated (adenosine diphosphate (ADP) 20 μM) platelets, before and after each dosing period.Results: At baseline there was no difference in platelet activation markers, either unstimulated or ADP-stimulated, between NE and VE. Pras 5 mg reduced both ADP-stimulated platelet P-selectin and activated GPIIb–IIIa in VE (p <0.01 for both analyses) and NE (p <0.001 and p <0.05, respectively). Clop 75 mg had a similar effect as Pras 5 mg but did not significantly reduce activated GPIIb–IIIa in VE. Prasugrel 10 mg resulted in decreased platelet activation in both age groups compared to Clop 75 mg (p <0.01).Conclusions: In VE and NE-patients, Pras 5 mg inhibited platelet P-selectin expression similar to Clop 75 mg and Pras 10 mg. Prasugrel 10 mg inhibited platelet P-selectin expression better than Clop 75 mg. Prasugrel 10 mg and 5 mg, but not Clop 75 mg, significantly inhibited activated GPIIb–IIIa in VE. This platelet reactivity data support the use of Pras 5 mg for VE patients.
(Less)
- author
- Wagner, Henrik
LU
; Lood, Christian
LU
; Borna, Catharina
LU
; Gidlöf, Olof
LU
; Truedsson, Lennart
LU
; Brown, Patricia
; Zhou, Chunmei
; Winters, Kenneth
; Jakubowski, Joseph A.
and Erlinge, David
LU
- organization
- publishing date
- 2016-10
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Activated GPIIb–IIIa, Platelets, Prasugrel, Surface P-selectin
- in
- Journal of Thrombosis and Thrombolysis
- volume
- 42
- issue
- 3
- pages
- 7 pages
- publisher
- Springer
- external identifiers
-
- wos:000382868700009
- pmid:27165280
- scopus:84966564902
- ISSN
- 0929-5305
- DOI
- 10.1007/s11239-016-1372-1
- project
- Helsingborg Resuscitation and Cardiovascular Research Group
- language
- English
- LU publication?
- yes
- id
- be2dbfa7-94b2-4ec4-8d09-80864a906deb
- date added to LUP
- 2016-06-02 16:29:57
- date last changed
- 2025-01-12 07:00:11
@article{be2dbfa7-94b2-4ec4-8d09-80864a906deb, abstract = {{<p>Platelet P-selectin and activated glycoprotein IIb–IIIa (GPIIb–IIIa) are markers of platelet activation and mediates platelet aggregation. Prasugrel (Pras) 5 mg may be used in very elderly (VE) acute coronary syndrome (ACS) patients undergoing PCI, but its effect on platelet P-selectin and activated GPIIb–IIIa in those patients is not known. Stable ACS patients, VE (78 ± 5 years, n = 23) and non-elderly (NE) (55 ± 5 years, n = 22) were randomized to Pras (5 or 10 mg) or clopidogrel (Clop) 75 mg during three 12-day periods. Platelet activation markers were measured by flow cytometry on unstimulated or stimulated (adenosine diphosphate (ADP) 20 μM) platelets, before and after each dosing period.Results: At baseline there was no difference in platelet activation markers, either unstimulated or ADP-stimulated, between NE and VE. Pras 5 mg reduced both ADP-stimulated platelet P-selectin and activated GPIIb–IIIa in VE (p <0.01 for both analyses) and NE (p <0.001 and p <0.05, respectively). Clop 75 mg had a similar effect as Pras 5 mg but did not significantly reduce activated GPIIb–IIIa in VE. Prasugrel 10 mg resulted in decreased platelet activation in both age groups compared to Clop 75 mg (p <0.01).Conclusions: In VE and NE-patients, Pras 5 mg inhibited platelet P-selectin expression similar to Clop 75 mg and Pras 10 mg. Prasugrel 10 mg inhibited platelet P-selectin expression better than Clop 75 mg. Prasugrel 10 mg and 5 mg, but not Clop 75 mg, significantly inhibited activated GPIIb–IIIa in VE. This platelet reactivity data support the use of Pras 5 mg for VE patients.</p>}}, author = {{Wagner, Henrik and Lood, Christian and Borna, Catharina and Gidlöf, Olof and Truedsson, Lennart and Brown, Patricia and Zhou, Chunmei and Winters, Kenneth and Jakubowski, Joseph A. and Erlinge, David}}, issn = {{0929-5305}}, keywords = {{Activated GPIIb–IIIa; Platelets; Prasugrel; Surface P-selectin}}, language = {{eng}}, number = {{3}}, pages = {{369--375}}, publisher = {{Springer}}, series = {{Journal of Thrombosis and Thrombolysis}}, title = {{Prasugrel 5 mg inhibits platelet P-selectin and GPIIb–IIIa expression in very elderly and non elderly : results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients}}, url = {{http://dx.doi.org/10.1007/s11239-016-1372-1}}, doi = {{10.1007/s11239-016-1372-1}}, volume = {{42}}, year = {{2016}}, }